Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

Trial Details

NCT ID

NCT06897644

Phase

PHASE3

Sponsor

Gruppo Oncologico del Nord-Ovest

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Oxaliplatin
Irinotecan (CPT-11)
Leucovorin
5-FU (5-fluorouracil)
gemcitabine
Nab-paclitaxel

Locations (sample)

Aviano, Italy, Italy|46.07056,12.59472
Bari, Italy, Italy|41.12066,16.86982
Brescia, Italy, Italy|45.53558,10.21472
Crema, Italy, Italy|45.36264,9.68176
Cremona, Italy, Italy|45.13325,10.02129

Key Eligibility Criteria

Patient able and willing to provide written informed consent and to comply with the study protocol.
Subjects must be ≥18 years.
Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic adenocarcinoma eligible for treatment in the first…
Presence of measurable or non-measurable disease assessed by CT scan and/or MRI according to RECIST 1.1. Note: any lesion which has been subjected …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →